These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 37357283)

  • 1. Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe.
    Iaccarino L; Burnham SC; Dell'Agnello G; Dowsett SA; Epelbaum S
    J Prev Alzheimers Dis; 2023; 10(3):426-442. PubMed ID: 37357283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between ante mortem Alzheimer's disease biomarkers in predicting neuropathology at autopsy.
    Wang ZB; Tan L; Wang HF; Chen SD; Fu Y; Gao PY; Ma YH; Guo Y; Hou JH; Zhang DD; Yu JT;
    Alzheimers Dement; 2023 Aug; 19(8):3613-3624. PubMed ID: 36840620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of the A/T/N profiles in PET, CSF, and plasma biomarkers with Alzheimer's disease neuropathology at autopsy.
    Wang ZB; Tan L; Gao PY; Ma YH; Fu Y; Sun Y; Yu JT;
    Alzheimers Dement; 2023 Oct; 19(10):4421-4435. PubMed ID: 37506291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
    Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
    Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy "In Vivo" in the Differential Diagnosis of Alzheimer's Dementia.
    Santangelo R; Dell'Edera A; Sala A; Cecchetti G; Masserini F; Caso F; Pinto P; Leocani L; Falautano M; Passerini G; Martinelli V; Comi G; Perani D; Magnani G
    Curr Alzheimer Res; 2019; 16(7):587-595. PubMed ID: 31345148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD; Rembach A; Villemagne VL; Varghese S; Rainey-Smith S; Sarros S; Evered LA; Fowler CJ; Pertile KK; Rumble RL; Trounson B; Taddei K; Laws SM; Macaulay SL; Bush AI; Ellis KA; Martins R; Ames D; Silbert B; Vanderstichele H; Masters CL; Darby DG; Li QX; Collins S;
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
    van Harten AC; Wiste HJ; Weigand SD; Mielke MM; Kremers WK; Eichenlaub U; Dyer RB; Algeciras-Schimnich A; Knopman DS; Jack CR; Petersen RC
    Alzheimers Dement; 2022 Apr; 18(4):635-644. PubMed ID: 34310035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropathological changes associated with aberrant cerebrospinal fluid p-tau181 and Aβ42 in Alzheimer's disease and other neurodegenerative diseases.
    Kurihara M; Matsubara T; Morimoto S; Arakawa A; Ohse K; Kanemaru K; Iwata A; Murayama S; Saito Y
    Acta Neuropathol Commun; 2024 Mar; 12(1):48. PubMed ID: 38539238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATN status in amnestic and non-amnestic Alzheimer's disease and frontotemporal lobar degeneration.
    Cousins KAQ; Irwin DJ; Wolk DA; Lee EB; Shaw LMJ; Trojanowski JQ; Da Re F; Gibbons GS; Grossman M; Phillips JS
    Brain; 2020 Jul; 143(7):2295-2311. PubMed ID: 32666090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges in Alzheimer's Disease Diagnostic Work-Up: Amyloid Biomarker Incongruences.
    Lombardi G; Pupi A; Bessi V; Polito C; Padiglioni S; Ferrari C; Lucidi G; Berti V; De Cristofaro MT; Piaceri I; Bagnoli S; Nacmias B; Sorbi S
    J Alzheimers Dis; 2020; 77(1):203-217. PubMed ID: 32716357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics.
    Zetterberg H; Blennow K
    Mol Neurodegener; 2021 Feb; 16(1):10. PubMed ID: 33608044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.